Log in

Relevant bibliographies by topics / Clinical trials; drug discovery; drug repurp

Contents

Journal articles
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Clinical trials; drug discovery; drug repurp'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Clinical trials; drug discovery; drug repurp.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Clinical trials; drug discovery; drug repurp"

1

Sakshi, Kaushik* Priyal Jain. "Drug Repurposing an Effective Tool in Modern Drug Discovery." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 2652–56. https://doi.org/10.5281/zenodo.15432771.

Full text

Abstract:

Drug repurposing is using an existing drug for a new treatment that was not indicated before. It has received immense attention during theCOVID-19 pandemic emergency. Drug repurposing has become the need of time to fasten the drug discovery process and find quickersolutionsto the over- exerted healthcare scenario and drug needs. Drug repurposing involve side notifying the drug, evaluatingits efficiency using preclinical models, and proceeding to phase II clinical trials. Identification of the drug candidate can be made through computational and experimental approaches. This approach usually ut

APA, Harvard, Vancouver, ISO, and other styles

2

Galustian, Christine, and Angus G. Dalgleish. "Article Commentary: The Power of the Web in Cancer Drug Discovery and Clinical Trial Design: Research without a Laboratory?" Cancer Informatics 9 (January 2010): CIN.S3191. http://dx.doi.org/10.4137/cin.s3191.

Full text

Abstract:

The discovery of effective cancer treatments is a key goal for pharmaceutical companies. However, the current costs of bringing a cancer drug to the market in the USA is now estimated at $1 billion per FDA approved drug, with many months of research at the bench and costly clinical trials. A growing number of papers highlight the use of data mining tools to determine associations between drugs, genes or protein targets, and possible mechanism of actions or therapeutic efficacy which could be harnessed to provide information that can refine or direct new clinical cancer studies and lower costs.

APA, Harvard, Vancouver, ISO, and other styles

3

Płocinska, Renata, Malgorzata Korycka-Machala, Przemyslaw Plocinski, and Jaroslaw Dziadek. "Mycobacterial DNA Replication as a Target for Antituberculosis Drug Discovery." Current Topics in Medicinal Chemistry 17, no. 19 (2017): 2129–42. http://dx.doi.org/10.2174/1568026617666170130114342.

Full text

Abstract:

Background: Mycobacterium tuberculosis (M. tuberculosis), the causative agent of tuberculosis, is a leading infectious disease organism, causing millions of deaths each year. This serious pathogen has been greatly spread worldwide and recent years have observed an increase in the number of multi-drug resistant and totally drug resistant M. tuberculosis strains (WHO report, 2014). The danger of tuberculosis becoming an incurable disease has emphasized the need for the discovery of a new generation of antimicrobial agents. The development of novel alternative medical strategies, new drugs and th

APA, Harvard, Vancouver, ISO, and other styles

4

Kawabata, Shinji, Hiroyuki Nakamura, Kohei Tsujino, et al. "10112- ET-10 EVALUATING PBC-IP AS A NOVEL BORON CARRIER IN BNCT." Neuro-Oncology Advances 6, Supplement_4 (2024): iv5. http://dx.doi.org/10.1093/noajnl/vdae173.019.

Full text

Abstract:

Abstract This study aims to expand the application scope of boron neutron capture therapy (BNCT) for BPA-insensitive cancers. To apply BNCT in the treatment of brain tumors, convection-enhanced delivery (CED) is used as the drug administration method. CED is expected to enhance therapeutic efficacy by delivering drugs directly to tumor tissues. Therefore, the development of BNCT necessitates planning non-clinical trials from both pharmaceutical and medical device perspectives, including tests on standards, quality, and safety for clinical trial implementation. Previous investigations have demo

APA, Harvard, Vancouver, ISO, and other styles

5

Owen, Dafydd R., Charlotte M. N. Allerton, Annaliesa S. Anderson, et al. "An oral SARS-CoV-2 M ^pro inhibitor clinical candidate for the treatment of COVID-19." Science 374, no. 6575 (2021): 1586–93. http://dx.doi.org/10.1126/science.abl4784.

Full text

Abstract:

Path to another drug against COVID-19 The rapid development of vaccines has been crucial in battling the ongoing COVID-19 pandemic. However, access challenges remain, breakthrough infections occur, and emerging variants present increased risk. Developing antiviral therapeutics is therefore a high priority for the treatment of COVID-19. Some drug candidates in clinical trials act against the viral RNA-dependent RNA polymerase, but there are other viral enzymes that have been considered good targets for inhibition by drugs. Owen et al . report the discovery and characterization of a drug against

APA, Harvard, Vancouver, ISO, and other styles

6

Rabinowitz, J. "What do Clinical Trials Tell us About Antidepressant Delayed Onset of Action?" European Psychiatry 41, S1 (2017): S3—S4. http://dx.doi.org/10.1016/j.eurpsy.2017.01.018.

Full text

Abstract:

Response to antidepressants in major depressive disorder is highly variable and determinants are not well understood. Presentation will provide clinical trial data on time to response and determinants of response to antidepressant treatment. Data is from the Innovative Medicines Initiative funded NEWMEDS collaboration, a large public-private collaboration which assembled the largest dataset of individual patient level information from randomized placebo-controlled trials of antidepressant drugs. Studies were conducted by four large pharmaceutical companies. Dataset includes placebo-controlled

APA, Harvard, Vancouver, ISO, and other styles

7

Kimmelman, Jonathan. "Ethics at Phase 0: Clarifying the Issues." Journal of Law, Medicine & Ethics 35, no. 4 (2007): 727–33. http://dx.doi.org/10.1111/j.1748-720x.2007.00194.x.

Full text

Abstract:

Many commentators have expressed concern that large investments in biomedical research over the past two decades have not been translated effectively into clinical applications. In its Critical Path Report, the Food and Drug Administration (FDA) characterized the problem as a “technological disconnect between discovery and the product development process,” and documented that the number of investigational new drugs (INDs) submitted to the agency had declined “significantly” since 2000. Along a similar vein, another study found that only five of 101 basic science studies showing significant the

APA, Harvard, Vancouver, ISO, and other styles

8

Bonaventura, Gabriele, Rosario Iemmolo, Giuseppe Antonino Attaguile, et al. "iPSCs: A Preclinical Drug Research Tool for Neurological Disorders." International Journal of Molecular Sciences 22, no. 9 (2021): 4596. http://dx.doi.org/10.3390/ijms22094596.

Full text

Abstract:

The development and commercialization of new drugs is an articulated, lengthy, and very expensive process that proceeds through several steps, starting from target identification, screening new leading compounds for testing in preclinical studies, and subsequently in clinical trials to reach the final approval for therapeutic use. Preclinical studies are usually performed using both cell cultures and animal models, although they do not completely resume the complexity of human diseases, in particular neurodegenerative conditions. To this regard, stem cells represent a powerful tool in all step

APA, Harvard, Vancouver, ISO, and other styles

9

Grossman, Stuart, Carlos Romo, Michelle Rudek-Renaut, et al. "ACTR-58. BASELINE REQUIREMENTS FOR NOVEL AGENTS BEING CONSIDERED FOR BRAIN CANCER EFFICACY TRIALS: REPORT OF AN ABTC WORKSHOP." Neuro-Oncology 21, Supplement_6 (2019): vi27. http://dx.doi.org/10.1093/neuonc/noz175.100.

Full text

Abstract:

Abstract Despite advances in the understanding of molecular pathways, the availability of NGS panels to identify potentially drugable mutations, the proliferation of targeted therapies, and the progress seen in other cancers, only one novel agent (temozolomide) has significantly improved the survival of patients with glioblastoma in the past three decades. A major factor distinguishing brain cancer from other malignancies is the presence of the blood-brain barrier that restricts entry into the central nervous system of over 95% of drugs currently approved by the FDA. Clinical investigators hav

APA, Harvard, Vancouver, ISO, and other styles

10

Mohapatra, Sovesh, Prathul Nath, Manisha Chatterjee, et al. "Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking." PLOS ONE 15, no. 11 (2020): e0241543. http://dx.doi.org/10.1371/journal.pone.0241543.

Full text

Abstract:

Background The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months. As the virus infected cases and mortality rate of this disease is increasing exponentially, scientists and researchers all over the world are relentlessly working to understand this new virus along with possible treatment regimens by discovering active therapeutic agents and vaccines. So, there is an urgent requirement of new and effective medications that can treat the disease caused by SARS-CoV-2. Methods and findings We perform the s

APA, Harvard, Vancouver, ISO, and other styles

More sources

Books on the topic "Clinical trials; drug discovery; drug repurp"

1

Herrling, Paul L., Alex Matter, and Markus Rudin, eds. Imaging in Drug Discovery and Early Clinical Trials. Birkhäuser Basel, 2005. http://dx.doi.org/10.1007/3-7643-7426-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chakraborty, Partha, and Amit Nagal. Software innovations in clinical drug development and safety. Medical Information Science Reference, an imprint of IGI Global, 2016.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Julka, P. K. Becoming a successful clinical trial investigator: A step by step guide for developing a clinical trial site. DNA Press, 2009.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Manuel, Hidalgo. Principles of anticancer drug development. Springer, 2011.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

5

T, Borchardt Ronald, ed. Integration of pharmaceutical discovery and development: Case histories. Plenum Press, 1998.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

6

Institute of Medicine (U.S.). Forum on Drug Discovery, Development, and Translation and National Academies Press (U.S.), eds. Transforming clinical research in the United States: Challenges and opportunities : workshop summary. National Academies Press, 2010.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

7

Semiconductor Photochemistry and Photophysics: Determination, Analysis, and Applications for Drug Discovery (MOLECULAR AND SUPRAMOLECULAR PHOTOCHEMISTRY). Marcel Dekker, 2003.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Rudin, Markus. Imaging in Drug Discovery and Early Clinical Trials. Springer London, Limited, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Imaging in Drug Discovery and Early Clinical Trials (Progress in Drug Research). Birkhäuser Basel, 2005.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Imaging in Drug Discovery and Early Clinical Trials (Progress in Drug Research). Birkhäuser Basel, 2006.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Clinical trials; drug discovery; drug repurp"

1

Somberg, John. "Clinical Trials Methodology." In Drug Discovery and Development. CRC Press, 2019. http://dx.doi.org/10.1201/9781315113470-21.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Zanders, Edward D. "Clinical Trials." In The Science and Business of Drug Discovery. Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-57814-5_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Zanders, Edward D. "Clinical Trials." In The Science and Business of Drug Discovery. Springer US, 2011. http://dx.doi.org/10.1007/978-1-4419-9902-3_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Perez, Daniel I., Carmen Gil, and Ana Martinez. "Chapter 9. Tau Protein Kinases Inhibitors: From the Bench to the Clinical Trials." In Drug Discovery. Royal Society of Chemistry, 2010. http://dx.doi.org/10.1039/9781849731065-00173.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

George, Bobby, Shrinivas Krishnarao Kulkarni, and Nilima A. Kshirsagar. "Regulatory Requirements and Quality Standards in India’s Clinical Trials Journey." In Drug Discovery and Drug Development. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-8002-4_12.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Theunissen, Eef. "Phase 1 Clinical Trials in Psychopharmacology." In Modern CNS Drug Discovery. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-62351-7_16.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Theunissen, Eef. "Phase 1 Clinical Trials in Psychopharmacology." In Modern CNS Drug Discovery. Springer Nature Switzerland, 2024. https://doi.org/10.1007/978-3-031-61992-2_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Chrubasik, Sigrun. "Natural Products in Clinical Trials." In Plant Bioactives and Drug Discovery. John Wiley & Sons, Inc., 2012. http://dx.doi.org/10.1002/9781118260005.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Vickers, Steven P., Helen C. Jackson, and Sharon C. Cheetham. "Chapter 6. New Drug Design and Therapeutic Development for Weight Reduction: Preclinical Studies and Clinical Trials." In Drug Discovery. Royal Society of Chemistry, 2015. http://dx.doi.org/10.1039/9781782622390-00090.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Parke, Tom. "Simulating Clinical Trials." In Systems Biology in Drug Discovery and Development. John Wiley & Sons, Inc., 2011. http://dx.doi.org/10.1002/9781118016435.ch11.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Clinical trials; drug discovery; drug repurp"

1

Lee, Seungyeon, Ruoqi Liu, Feixiong Cheng, and Ping Zhang. "A Deep Subgrouping Framework for Precision Drug Repurposing via Emulating Clinical Trials on Real-world Patient Data." In KDD '25: The 31st ACM SIGKDD Conference on Knowledge Discovery and Data Mining. ACM, 2025. https://doi.org/10.1145/3690624.3709418.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Albuquerque, Pedro José Honório de, Laura Guerra Lopes, Jordy Silva de Carvalho, Luzilene Pereira de Lima, and Marina Galdino da Rocha Pitta. "Emerging therapies for amyotrophic lateral sclerosis applied to drug discovery." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.021.

Full text

Abstract:

Background: Amyotrophic Lateral Sclerosis (ALS) is a progressive neuromuscular disease mainly caused by genetic disorders. This progressive disorder involves the degeneration of motor neurons at various levels. Drugs have been studied, and they show improvement in survival and reduced progression of the disease, they are riluzole and edaravone. Objectives: Investigate emerging therapies for the treatment of ALS. Methods: The Pubmed database was used to conduct the research, and the keywords were “Amyotrophic Lateral Sclerosis”, “Emerging”, “Therapies”,”Drugs”, all present in Mesh. Articles fro

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Clinical trials; drug discovery; drug repurp"

1

Alwagdani, Abdullah. Review Of mPGES-1 Inhibitors Based On The Benzoxazole And Its Isostere Scaffold For The Treatment Of Inflammatory Diseases. University of Tennessee Health Science Center, 2024. http://dx.doi.org/10.21007/com.lsp.2024.0021.

Full text

Abstract:

The vital role of the prostanoid pathway in inflammation, pain, cancer, Alzheimer’s and many other diseases has attracted the drug discovery community to discover targets for therapeutic development. Although existing non-steroidal anti-inflammatory drugs (NSAIDs) inhibiting cyclooxygenases (COX) are widely used, the side effects of these NSAIDs limit the ling time medication. Microsomal prostaglandin E synthase-1 (mPGES-1) is an attractive target that is overexpressed during inflammations, and it could be a safe alternative to NSAIDs for treating inflammatory diseases.Since the discovery of m

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!